Loading...

ACRV ACRIVON THERAPEUTICS INC Expansion Plans 8-K Filing

CRVN

CRV

ACRIVON THERAPEUTICS INC

(ACRV)

2026 8-K

Financial Update

Laboratory Agreement Termin...

KOL Panel Webcast

Corporate Webcast Update

Financial Update

Quarterly Results

Business Update

Financial Results Announcement

Financial Statements

Management Change

Financial Results

Financial Update

Management Changes

Financial Results

Clinical Trial Update

Clinical Data Update

Financial Results

Annual Meeting Results

Financial Results Announcement

Results of Operations and F...

Private Placement

Financial Results Announcement

Appointment of Director

Appointment of Director

Participation in Conference

Investment Agreement

Financial Results Announcement

Earnings Reports

Annual Meeting Results

Amended Employment Agreement

Financial Results Announcement

Financial Update

Conference Participation

Financial Results Announcement

Results of Operations and F...

Annual Meeting and Proposal...

External Links:

On January 8, 2026, Acrivon Therapeutics disclosed preliminary cash of approximately $119 million as of December 31, 2025, expected to fund operations until Q2 2027. The company also announced promising clinical data for its ACR-368 and ACR-2316 projects and plans to expand trials in Europe.

AI Assistant

ACRIVON THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.